多くの人々は、テストされていない新しい抗ウイルス薬が腎臓に永久的な損傷を与えることを恐れています。 ファビピラビルは告発されたが無罪となった✨ アビガン論文、たくさん出てくるよ🥰
1-1-2022: Many people fear that new, untested antivirals will permanently damage their kidneys. Favipiravir was accused but acquitted: https://t.co/Ev0REcYsm4 https://t.co/yqE4C2xo0l https://t.co/Qk3N7Fm9pp https://t.co/bMpiFtTNdz https://t.co/BdjGmmvrPK
@cBeyondObvious @Shottanneshiji For Covid, useless and toxic too https://t.co/aAYLfrt5x4 https://t.co/t5vKcZrQEB https://t.co/Gu2KvgCakZ
Kaynak: https://t.co/78P0GDKCfj
Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events | IDR @DovePress https://t.co/dGretfk3HT
2021: In a study just released from Brussels, Belgium, "Low-dose favipiravir therapy was well tolerated in these 4 critically ill COVID-19 patients, however, higher doses might be needed" https://t.co/LVggQ07Gx2 WHO: "Favipiravir is a relatively safe drug"
アビガンを新型コロナに用いた場合の副作用。WHOデータ。多数の被験者がなく、医学統計的判断不能。使うなら同意書必須。国は賠償の用意を。 [Full text] Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events | IDR @DovePress https://t.co/nf458AZaVL
Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database https://t.co/DgEYLpzA1G
RT @gmCdqONEEyVxc8r: 2020年12月14日:WHOは「ファビピラビルは比較的安全な薬のようだ」と述べていますが、レムデシビルはそうではありません WHO、大々的にアピールしてほしい😊 https://t.co/L18ENIXxAW
2020年12月14日:WHOは「ファビピラビルは比較的安全な薬のようだ」と述べていますが、レムデシビルはそうではありません WHO、大々的にアピールしてほしい😊
12-14-2020: WHO says "favipiravir appears to be a relatively safe drug," remdesivir not https://t.co/3BkvmkRbbF https://t.co/Cxp3FbBBpR https://t.co/AMqOWXDbYe https://t.co/DLOpvXxu9d https://t.co/y6GGtAnZqL https://t.co/pvx5DIgDdg https://t.co/PlKrlOl7yB
Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database https://t.co/Osdp2VVmCq
12-14-2020: From WHO: "Conclusion: This study revealed that favipiravir appears to be a relatively safe drug. An undiscovered anti-inflammatory activity of favipiravir may explain the improvement in critically ill patients and reduce inflammatory markers"
My article is featured on the @ResearchGate #COVID19 community page. Read it here: https://t.co/C28j2rie56
結論:この研究は、ファビピラビルが比較的安全な薬であるように見えることを明らかにしました✨。ファビピラビルの未発見の抗炎症作用は、重症患者の改善を説明し、炎症マーカーを減らす可能性があります。現在、データはごく少数の患者に基づいています。 マレーシア👌 https://t.co/7Nk1bbphQA
Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events | IDR @DovePress https://t.co/Ow6CHhAGVP